HYPR Stock Overview A medical device company, provides magnetic resonance imaging (MRI) products in the United States, Europe, and Middle Eastern Markets. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Hyperfine, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Hyperfine Historical stock prices Current Share Price US$0.86 52 Week High US$1.39 52 Week Low US$0.76 Beta 0.85 1 Month Change -15.69% 3 Month Change -17.31% 1 Year Change -16.50% 3 Year Change -89.11% 5 Year Change n/a Change since IPO -91.41%
Recent News & Updates
Hyperfine, Inc. Announces Extensive Clinical Study Coverage At Radiological Society of North America 2024, Showcasing the Body of Evidence Supporting the Use of the Swoop System Across Different Sites of Care Dec 05
Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results Nov 15
Hyperfine, Inc. Updates Revenue Guidance for the Year 2024 Nov 14
Hyperfine, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 25
Hyperfine, Inc. Revises Revenue Guidance for the Year 2024 Aug 10
Hyperfine, Inc. Revises Revenue Guidance for the Year 2024 Aug 09 See more updates
Hyperfine, Inc. Announces Extensive Clinical Study Coverage At Radiological Society of North America 2024, Showcasing the Body of Evidence Supporting the Use of the Swoop System Across Different Sites of Care Dec 05
Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results Nov 15
Hyperfine, Inc. Updates Revenue Guidance for the Year 2024 Nov 14
Hyperfine, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 25
Hyperfine, Inc. Revises Revenue Guidance for the Year 2024 Aug 10
Hyperfine, Inc. Revises Revenue Guidance for the Year 2024 Aug 09
Hyperfine Announces Presentation of Initial Data from Observational Clinical Studies Evaluating the Use of Portable MR Brain Imaging for Alzheimer's Patients Jul 30
Hyperfine, Inc. Announces FDA Clearance of Software Update That Enables Faster Acquisition of Best-In-Class Ultra-Low-Field Brain Images Jul 18
Hyperfine, Inc. Highlights Positive Results from Multi-Site Observational Study on Swoop® System for Stroke Assessment Jul 16
Hyperfine, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 12
Hyperfine Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Inclusion on the Nasdaq Global Market Jun 01
Hyperfine, Inc. Provides Earnings Guidance for the Year 2024 May 15
Hyperfine, Inc. to Report Q1, 2024 Results on May 13, 2024 May 01
Hyperfine, Inc., Annual General Meeting, Jun 11, 2024 Apr 28
Hyperfine, Inc. Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in Care PMR Study Apr 17
Hyperfine, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 Mar 23
Hyperfine, Inc. Launches AI-Powered Brain Imaging Software for Enhanced Image Quality and Ease of Use Jan 09
Hyperfine, Inc. Provides Earnings Guidance for the Full Year 2023 Nov 12
Hyperfine, Inc. Completes Enrollment for Hope Pmr Pediatric Hydrocephalus Study Using Hyperfine, Inc. Portable Mr. Imaging System Aug 10
Hyperfine, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Jul 25
Hyperfine, Inc. Announces Executive Changes Jul 21
Hyperfine, Inc. Provides Earnings Guidance for the Year 2023 May 12
Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop Portable MR Imaging System Feb 15
Hyperfine, Inc. Announces New Data Regarding the Use of the Swoop System in Stroke Patient Follow-Up Feb 10 Hyperfine, Inc. Announces Chief Financial Officer Changes
Hyperfine, Inc. Announces Termination of Neela Paykel as General Counsel, Chief Compliance Officer, and Corporate Secretary Dec 10
Hyperfine Notifies the Nasdaq Listing Qualifications Staff Nov 15
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 12
Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022 Nov 11
Hyperfine, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 28 Hyperfine Names Maria Sainz as Chief Executive Officer, Effective October 24, 2022
Hyperfine appoints Maria Sainz as President, CEO Oct 06
Consensus forecasts updated Aug 18
Founder & Vice Chairman recently bought US$442k worth of stock Aug 14
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 12
Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022 Aug 11
Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M Aug 10
Hyperfine, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Jul 21
Hyperfine, Inc. Announces Zero Radiation Dose Rapid MR Imaging Test for Pediatric Hydrocephalus Patients Jul 15
Hyperfine, Inc. Announces Executive Changes, Effective July 29, 2022 Jun 30
Hyperfine stock plunges 14% as CEO Dave Scott steps down Jun 29
Founder & Vice Chairman recently bought US$119k worth of stock Jun 17
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 13
Hyperfine, Inc. Provides Revenue Guidance for the Full Year 2022 May 12
High number of new and inexperienced directors Apr 27
Hyperfine, Inc., Annual General Meeting, Jun 08, 2022 Apr 26
Hyperfine, Inc. to Report Q1, 2022 Results on May 11, 2022 Apr 21
Hyperfine (NASDAQ:HYPR) Is In A Good Position To Deliver On Growth Plans Apr 04
Hyperfine: MR Imaging In A Swoop Mar 09
Hyperfine, Inc. to Report Q4, 2021 Results on Mar 23, 2022 Mar 06
Hyperfine Appoints Chip Truwit, M.D. as Senior Medical Director Feb 09
Hyperfine, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021 Jan 12
Hyperfine, Inc. announced a financing transaction Dec 30 Shareholder Returns HYPR US Medical Equipment US Market 7D -8.5% -1.1% -2.2% 1Y -16.5% 10.1% 23.9%
See full shareholder returns
Return vs Market: HYPR underperformed the US Market which returned 23.9% over the past year.
Price Volatility Is HYPR's price volatile compared to industry and market? HYPR volatility HYPR Average Weekly Movement 6.9% Medical Equipment Industry Average Movement 7.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: HYPR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HYPR's weekly volatility (7%) has been stable over the past year.
About the Company Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States, Europe, and Middle Eastern Markets. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors.
Show more Hyperfine, Inc. Fundamentals Summary How do Hyperfine's earnings and revenue compare to its market cap? HYPR fundamental statistics Market cap US$62.74m Earnings (TTM ) -US$41.01m Revenue (TTM ) US$13.26m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HYPR income statement (TTM ) Revenue US$13.26m Cost of Revenue US$7.16m Gross Profit US$6.10m Other Expenses US$47.11m Earnings -US$41.01m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.56 Gross Margin 46.01% Net Profit Margin -309.42% Debt/Equity Ratio 0%
How did HYPR perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 23:02 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Hyperfine, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Yuan Zhi B. Riley Securities, Inc. Vijay Kumar Evercore ISI Xuyang Li Jefferies LLC
Show 1 more analysts 
